Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terbutaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.96 |
| ▸ | LMNA | P02545 | 4/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.96 |
| ▸ | TSHR | P16473 | 4/20 | 0.96 |
| ▸ | CASP7 | P55210 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | CASP1 | P29466 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terbutaline SCHEMBL41869 | 0.98 | LMNA (1.00) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL4391 | 0.98 | LMNA (1.00) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL13327959 | 0.98 | LMNA (1.00) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL11703058 | 0.96 | ADRB2 (0.96) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL16553265 | 0.92 | LMNA (0.81) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL9524623 | 0.92 | LMNA (0.97) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL9585756 | 0.91 | LMNA (0.94) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL9614480 | 0.90 | LMNA (1.00) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL5178614 | 0.90 | LMNA (1.00) | ADRB2LMNAHIF1ATSHRCASP7 | |
| Terbutaline SCHEMBL41870 | 0.90 | LMNA (1.00) | ADRB2LMNAHIF1ATSHRCASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101453993-A | Controlled release delivery device containing organosol coating | ISA ODIDI (CA) | 2009-06-10 | — | — | CN | claimed |
| US-20260144747-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4606435-A2 | PHARMACEUTICAL COMPOSITION COMPRISING POORLY SOLUBLE BASIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4316598-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY SOLUBLE BASIC AGENT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-06-18 | — | — | EP | disclosed |
| CN-119418898-A | Method and model for prognosis/cost-effectiveness evaluation of chronic obstructive pulmonary disease | 山西医科大学第二医院(山西医科大学第二临床医学院) | 2025-02-11 | — | — | CN | disclosed |
| EP-4424313-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-09-04 | — | — | EP | disclosed |
| CN-112384223-B | Pharmaceutical composition containing poorly soluble basic agent | 中外制药株式会社 | 2024-08-27 | — | — | CN | disclosed |
| US-20240190807-A1 | A METHOD FOR PREPARING R-TERBUTALINE USING CHIRAL AUXILIARY GROUPS | SUZHOU HOMESUN PHARMACEUTICAL CO, LTD. (CN) | 2024-06-13 | — | — | US | disclosed |
| CN-118159274-A | Syrup preparation | 中外制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-20120021059-A1 | SOLID PREPARATION | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8034801-B2 | Analgesic agent | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20090253729-A1 | Analgesic Agent | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2039359-A1 | ANALGESIC AGENT | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-7205425-B2 | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof | CHISSO CORPORATION (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20070060656-A1 | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof | SHIBASAKI MASAKATSU | 2007-03-15 | — | — | US | disclosed |
| US-20050148801-A1 | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof | JNC CORPORATION (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6632955-B1 | Optically active 1-substituted phenyl-2-nitro alcohol derivatives which are useful pharmaceutical intermediates. Enantiomotphs active 1-substituted phenyl-2-nitro alcohol derivatives. From these nitro alcohol such as albutramin and | CHISSO CORPORATION (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20020193447-A1 | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof | JNC CORPORATION (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0947498-A1 | OPTICALLY ACTIVE NITRO ALCOHOL DERIVATIVES, OPTICALLY ACTIVE AMINO ALCOHOL DERIVATES, AND PROCESS FOR PREPARING THE SAME | CHISSO CORPORATION (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148801-A1 | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof | ADH1A, ALDH7A1, ADRB1 | ADRB2 12/4885LMNA 2604/4885HIF1A 1996/4885 |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | KCNN2, KCNN1, KIT | ADRB2 2077/4885LMNA 1055/4885HIF1A 4420/4885 |
| US-20240190807-A1 | A METHOD FOR PREPARING R-TERBUTALINE USING CHIRAL AUXILIARY GROUPS | HBB, TERT, ADRB2 | ADRB2 3/4885LMNA 2500/4885HIF1A 4423/4885 |
| US-20070060656-A1 | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof | ADH1A, ALDH7A1, ADRB1 | ADRB2 12/4885LMNA 2604/4885HIF1A 1996/4885 |
| US-20260144747-A1 | SYRUP PREPARATION | ALK, IRAK1, IRAK3 | ADRB2 2541/4885LMNA 2736/4885HIF1A 3533/4885 |
| US-20020193447-A1 | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof | ADH1A, ALDH7A1, SARM1 | ADRB2 13/4885LMNA 2693/4885HIF1A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.